# Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy

> **NCT01611155** · NA · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 50 (actual)

## Conditions studied

- Peripheral Neuropathy

## Interventions

- **DRUG:** venlafaxine
- **DRUG:** placebo
- **OTHER:** questionnaire administration
- **OTHER:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT01611155
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-17
- **Primary completion:** 2014-03-07
- **Final completion:** 2015-09-23
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01611155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01611155, "Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01611155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*